IQVIA Laboratories bioanalytical lab’s expert TL1A program collaboration with leading pharma company

The Target - IBD

Tumor necrosis factor α-like ligand 1A (TL1A) has been a recent therapeutic target of interest for its role in inflammatory bowel disease (IBD). Current studies suggest TL1A is upregulated in patients with IBD, making compounds that inhibit it worthy of clinical analysis (Fig 1). A recent publication features one such TL1A-inhibiting compound in a Phase 1 dose-escalation study to monitor its effects on total TL1A, in collaboration with IQVIA Laboratories.

 

The Challenge

Accurate quantitation of the TL1A biomarker has remained a challenge in the industry due to its size (28 kDa¹) as well as the limited availability of a platform that can deliver the desired sensitivity.

 

The Solution

At IQVIA Laboratories we utilize hybrid LBA/LC-MS methods employing low flow chromatography and high-resolution mass spectrometry that are capable of measuring biomarkers in the sub-pg/mL range. Using this technology, we were able to deliver TL1A concentrations from human samples with the desired sensitivity. This reliable data allows our customers to make informed decisions about their pipelines. We have both the experience and platform methodologies to continue examining TL1A - progressing the treatment options available for afflicted patients.

 

The Right Partner

IQVIA Laboratories is leading with science and has over 16 years of experience utilizing hybrid LBA/LC-MS methods for quantifying biological targets for both preclinical and clinical programs.

 

• Cutting-edge low-flow LC/HRMS platform drives the low sensitivity required with an experienced staff to operate them
• We’ve analyzed over a half-million samples to date, delivering data our customers depend on for advancing the drug development landscape
• Our staff has both the experience and passion to develop new methods used for quantitative analysis, and a drive to help serve patients this data is used for

References:

Figure 1: The mechanism of TL1A²

Xu, W.-D., Li, R., & Huang, A.-F. (2022). Role of TL1A in inflammatory autoimmune diseases: A comprehensive review. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.891328

Valatas, V., Kolios, G., & Bamias, G. (2019). TL1A (TNFSF15) and DR3 (TNFRSF25): A co-stimulatory system of cytokines with diverse functions in gut mucosal immunity. Frontiers in Immunology, 10. https://doi.org/10.3389/fimmu.2019.00583